BioCentury
ARTICLE | Company News

Santaris, Servier, miRagen deal

July 14, 2014 7:00 AM UTC

The partners extended by two years to October 2016 a 2011 deal to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen’s preclinical programs targeting microRNA-208 ( miR-208) and miR-15/195, plus an undisclosed target to which Servier exercised an option in May 2013. miRagen received an upfront payment in 2011 and an additional payment last year with the option exercise. The company is eligible for R&D milestones per target, plus commercial milestones and royalties. Servier will continue to have rights outside of the U.S. and Japan and will be responsible for funding all development, regulatory and commercialization costs of the three candidates. miRagen retains U.S. and Japanese rights and will have an option to co-sponsor Phase III trials. The companies could not be reached for details (see BioCentury, Oct. 24, 2011 & June 3, 2013). ...